Results 91 to 100 of about 180,206 (347)

THE WAYS TO ENHANCE SAFETY OF COMBINATIONS OF DRUGS PROLONGING QT INTERVAL IN THE OUT-PATIENT AND POLYCLINIC PRACTICE

Вестник анестезиологии и реаниматологии, 2018
Prolongation of QT interval is a predictor of fatal disorders of cardiac rhythm and sudden death. Side effects of medications is one of the main causes of prolonged QT interval.
E. V. Shikh, Zh. M. Sizova, A. D. Ismagilov, M. A. Vyzhigina   +3 more
doaj   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Incidencia de QT corto y largo en alumnos de primer ingreso a Facultad de Deportes [PDF]

, 2015
Las alteraciones electrocardiográficas del intervalo QT (síndrome de QT corto y largo) están asociadas a un riesgo elevado de muerte súbita por arritmias ventriculares malignas y a episodios de fibrilación auricular.
Arce Guridi, Raquel Citlalli, Chávez López, Carlos Alberto, Galarraga Triana, Edgar Ney, Pineda Espejel, Heriberto Antonio, Trejo Trejo, Marina   +4 more
core  

Twenty-four-hour QT interval variability: Increased QT variability during sleep in patients with panic disorder [PDF]

, 2002
Recent studies on beat-to-beat QT interval variability (QTV) have shown that it can be used as a noninvasive measure of cardiac repolarization lability. It is also a predictor of sudden cardiac death and is higher in patients with anxiety and depression.
Balon, R., Jampala, V.C., Jayaraman, A., Pohl, R., Yeragani, V.K.   +4 more
core   +1 more source

Concentration–QTc Modeling to Support Clinical Development of Fezolinetant

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Fezolinetant is a non‐hormonal, selective neurokinin‐3 receptor antagonist that blocks neurokinin B activation of kisspeptin/neurokinin B/dynorphin neurons to thereby modulate neuronal activity in the thermoregulatory center. Fezolinetant has been approved in many regions, including North America, Europe, Asia, and Australia for the treatment ...
Jace C. Nielsen, Masako Saito, Xuegong Wang, Megumi Iwai, Graeme L. Fraser, Steven Ramael, Jiayin Huang   +6 more
wiley   +1 more source

Higher accuracy of concurrent use of corrected QT interval and procalcitonin serum level to predict sepsis related mortality in ICU patients [PDF]

, 2020
Reham Mustafa Hashim, Mai Mohsen Abdelaziz, Rasha Mahmoud Hassan   +2 more
openalex   +1 more source

Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor‐like kinase‐2 (ALK2) inhibitor, in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract The oral, small molecule inhibitor of activin receptor‐like kinase‐2, zilurgisertib (INCB000928), is under evaluation in fibrodysplasia ossificans progressiva. Cardiac safety was assessed using electrocardiogram (ECG) parameters and a plasma concentration‐heart rate‐corrected QT (C‐QTc) interval analysis of pooled data from single ascending ...
Yan‐ou Yang, Hong Yang, Xing Liu, Xiaohua Gong, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

A Phase 1, Randomized, Placebo‐Controlled, Multiple‐Dose, Double‐Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1, randomized, placebo‐controlled, double‐blind study assessed the pharmacokinetic profile of rimegepant (25, 75, or 150 mg once daily for 14 days) in healthy Japanese and Caucasian adults. Exposures were modestly increased in Japanese participants compared with Caucasian participants following a single dose of rimegepant (Day 1 ...
Rajinder Bhardwaj, Chay Ngee Lim, Yinhua Li, Kyle T. Matschke, Richard Bertz, Robert Croop, Jing Liu   +6 more
wiley   +1 more source

Short QT interval syndrome

Кардиоваскулярная терапия и профилактика, 1970
Every year, sudden cardiac death (SCD) takes lives of 400 000 American citizens, and in 10-20% ofthe cases, fatal outcome is explained by hereditary pathology.
I. G. Fomina, A. I. Tarzimanova, A. V. Vetluzhsky   +2 more
doaj